Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Donald Berry"'
Publikováno v:
Journal of Clinical and Translational Science, Vol 5, Pp 44-45 (2021)
ABSTRACT IMPACT: A one-stage Bayesian multilevel model for meta-analysis integrating different survival data is introduced to complete the information synthesis without assuming proportional hazard. OBJECTIVES/GOALS: To develop a general modeling app
Externí odkaz:
https://doaj.org/article/1914343c168c43959ae776f6003c888b
Autor:
Michael J Campbell, Denise Wolf, Rita A Mukhtar, Vickram Tandon, Christina Yau, Alfred Au, Frederick Baehner, Laura van't Veer, Donald Berry, Laura J Esserman
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e79114 (2013)
Tumor associated macrophages (TAMs) are recruited from the circulation to the tumor site, and can undergo a spectrum of phenotypic changes, with two contrasting activation states described in the literature: the M1 and M2 phenotypes. We previously id
Externí odkaz:
https://doaj.org/article/a1c3364fa97c4ef48180860b83b647b7
Autor:
Cedar Morrow Anderson, Christopher Joseph, Rick Fisher, Donald Berry, J. Brad Diestelhorst, Christine Kulstad, Marvin Wayne
Publikováno v:
Therapeutic Hypothermia and Temperature Management. 12:235-239
Although specific temperature targets are debated, targeted temperature management (TTM) is a common treatment for postcardiac arrest patients. However, consistently implementing a TTM protocol is challenging, especially in a community hospital. Ofte
Autor:
Razelle Kurzrock, Donald Berry, Sijin Wen, Yang Ye, Rajyalakshmi Luthra, Filip Janku, Aung Naing, Sarina Piha-Paul, Siqing Fu, Gerald S. Falchook, Jennifer J. Wheler, David S. Hong, Nancy G. Iskander, Apostolia-Maria Tsimberidou
PDF file, 113K, Supplemental Table 1. List of clinical trials by ID number; Supplemental Table 2. Distribution of Molecular Aberrations by Diagnosis; Supplemental Table 3. Distribution of Molecular Aberrations by Diagnosis; Supplemental Table 4. Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a9e22cdf24b73990f7098c079befb7
https://doi.org/10.1158/1078-0432.22447718.v1
https://doi.org/10.1158/1078-0432.22447718.v1
Autor:
Donald Berry, Razelle Kurzrock, Yang Ye, Kenneth Aldape, Filip Janku, Aung Naing, Sarina Piha-Paul, Siqing Fu, Gerald S. Falchook, Jennifer J. Wheler, David S. Hong, Sijin Wen, Apostolia-Maria Tsimberidou
Purpose: The purpose of this study was to confirm our previous results that targeted agents matched with tumor molecular alterations were associated with improved outcomes compared with nonmatched therapy in patients with advanced cancer.Experimental
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a111c7e263015ae3ab96e37a3f1ff4a
https://doi.org/10.1158/1078-0432.c.6523022.v1
https://doi.org/10.1158/1078-0432.c.6523022.v1
Autor:
Razelle Kurzrock, Donald Berry, Sijin Wen, Yang Ye, Rajyalakshmi Luthra, Filip Janku, Aung Naing, Sarina Piha-Paul, Siqing Fu, Gerald S. Falchook, Jennifer J. Wheler, David S. Hong, Nancy G. Iskander, Apostolia-Maria Tsimberidou
Purpose: We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations.Patient and Methods: Patients with advanced cancer were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb0285f64c005d875e11d4b40e9fc1f
https://doi.org/10.1158/1078-0432.c.6521174
https://doi.org/10.1158/1078-0432.c.6521174
Autor:
Donald Berry, Razelle Kurzrock, Yang Ye, Kenneth Aldape, Filip Janku, Aung Naing, Sarina Piha-Paul, Siqing Fu, Gerald S. Falchook, Jennifer J. Wheler, David S. Hong, Sijin Wen, Apostolia-Maria Tsimberidou
Supplemental Table 3. Types of agents used in patients treated with matched or non-matched therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11155a7ebaf1dfaa409d2c9893cfaedb
https://doi.org/10.1158/1078-0432.22455407.v1
https://doi.org/10.1158/1078-0432.22455407.v1
Autor:
Donald Berry, John Kath, Shams Lodhy, An Ly, Yingqi Shi, Allon Percus, Jeffrey Hyman, Kelly Moran, Philip Stauffer, Justin Strait, Matthew Sweeney, Hari Viswanathan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9b78b2b81ef5e0eeea14fea874570c1
https://doi.org/10.2172/1867148
https://doi.org/10.2172/1867148
Autor:
Ingo K. Mellinghoff, Brian Alexander, Donald Berry, Nicholas Blondin, Meredith Buxton, Webster Cavenee, Howard Colman, John de Groot, Macarena I. de la Fuente, Benjamin Ellingson, Gary Gordon, Emma M.V. Hyddmark, Mustafa Khasraw, Andrew Lassman, Eudocia Lee, Wenbin Li, Michael Lim, Tom Mikkelsen, Apoorva Nelli, James Perry, Erik Sulman, Kirk Tanner, Michael Weller, Patrick Y. Wen, Timothy Cloughesy
Publikováno v:
Cancer Research. 83:CT062-CT062
Background: GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a biomarker based, multi-arm, international, seamless Phase 2/3 Response Adaptive Randomization platform trial designed to rapidly identify experimental therapi
Autor:
Claudine Isaacs, Rita Nanda, Jo Chien, Meghna S. Trivedi, Erica Stringer-Reasor, Christos Vaklavas, Judy C. Boughey, Amy Sanford, Anne Wallace, Amy S. Clark, Alexandra Thomas, Kathy S. Albain, Laura C. Kennedy, Tara B. Sanft, Kevin Kalinsky, Hyo S. Han, Nicole Williams, Mili Arora, Anthony Elias, Carla Falkson, Smita Asare, Ruixiao Lu, Maria Pitsouni, Amy Wilson, Jane Perlmutter, Hope Rugo, Richard Schwab, W. Fraser Symmans, Nola M. Hylton, Laura Van’t Veer, Douglas Yee, Angela DeMichele, Donald Berry, Laura J. Esserman, null I-SPY Investigators
Publikováno v:
Cancer Research. 83:GS5-03
Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status to evaluate novel agents as neoadjuvant therapy for high-risk breast